520 related articles for article (PubMed ID: 29320890)
1. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.
Harrer DC; Dörrie J; Schaft N
Hum Gene Ther; 2018 May; 29(5):547-558. PubMed ID: 29320890
[TBL] [Abstract][Full Text] [Related]
2. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
3. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
5. Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF
Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833
[TBL] [Abstract][Full Text] [Related]
6. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
7. NKT cells - New players in CAR cell immunotherapy?
Kriegsmann K; Kriegsmann M; von Bergwelt-Baildon M; Cremer M; Witzens-Harig M
Eur J Haematol; 2018 Dec; 101(6):750-757. PubMed ID: 30187578
[TBL] [Abstract][Full Text] [Related]
8. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
9. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
Obajdin J; Davies DM; Maher J
Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
[TBL] [Abstract][Full Text] [Related]
10. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
13. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
Zhang PF; Xie D; Li Q
Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
[TBL] [Abstract][Full Text] [Related]
15. CAR-expressing NK cells for cancer therapy: a new hope.
Xia J; Minamino S; Kuwabara K
Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
17. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
[TBL] [Abstract][Full Text] [Related]
18. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cell Therapy.
Ogba N; Arwood NM; Bartlett NL; Bloom M; Brown P; Brown C; Budde EL; Carlson R; Farnia S; Fry TJ; Garber M; Gardner RA; Gurschick L; Kropf P; Reitan JJ; Sauter C; Shah B; Shpall EJ; Rosen ST
J Natl Compr Canc Netw; 2018 Sep; 16(9):1092-1106. PubMed ID: 30181421
[TBL] [Abstract][Full Text] [Related]
20. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]